Viatris Inc. (VTRS)

NASDAQ: VTRS · Real-Time Price · USD
14.58
+0.24 (1.67%)
At close: Feb 6, 2026, 4:00 PM EST
14.50
-0.08 (-0.55%)
After-hours: Feb 6, 2026, 7:55 PM EST
1.67%
Market Cap16.79B +26.3%
Revenue (ttm)14.12B -6.1%
Net Income-3.69B
EPS-3.13
Shares Out 1.15B
PE Ration/a
Forward PE6.05
Dividend$0.48 (3.35%)
Ex-Dividend DateNov 24, 2025
Volume8,459,267
Open14.24
Previous Close14.34
Day's Range14.10 - 14.60
52-Week Range6.85 - 14.60
Beta0.80
AnalystsHold
Price Target11.83 (-18.86%)
Earnings DateFeb 26, 2026

About VTRS

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]

Sector Healthcare
Founded 1961
Employees 32,000
Stock Exchange NASDAQ
Ticker Symbol VTRS
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for VTRS stock is "Hold." The 12-month stock price target is $11.83, which is a decrease of -18.86% from the latest price.

Price Target
$11.83
(-18.86% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, Febru...

3 days ago - PRNewsWire

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) anno...

3 days ago - PRNewsWire

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today anno...

Other symbols: LXRX
17 days ago - PRNewsWire

Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

24 days ago - Seeking Alpha

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing trans...

4 weeks ago - PRNewsWire

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference

4 weeks ago - GlobeNewsWire

Viatris Provides Pipeline Update on Four Regulatory Milestones

Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension) U.S. FDA Accepts New Drug Application for Low Dos...

7 weeks ago - PRNewsWire

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

PITTSBURGH , Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference ...

7 weeks ago - PRNewsWire

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Compete Restrictions PITTSBURGH , Dec. 6, 2025 /PR...

2 months ago - PRNewsWire

Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript

2 months ago - Seeking Alpha

Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

2 months ago - Seeking Alpha

Viatris to Participate in Upcoming Investor Conferences

PITTSBURGH , Nov. 24, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in Decembe...

2 months ago - PRNewsWire

Viatris Inc. (VTRS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Viatris Inc. ( VTRS) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Scott Smith - CEO & Director Theodora Mistras - Chief Financial Officer Philippe Ma...

2 months ago - Seeking Alpha

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

PITTSBURGH , Nov. 13, 2025 /PRNewswire/ --  Viatris Inc.  (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025 . The list of 25 global lead...

3 months ago - PRNewsWire

Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Viatris Inc. ( VTRS) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Theodora Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - U...

3 months ago - Seeking Alpha

Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript

Viatris Inc. ( VTRS) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants William Szablewski Scott Smith - CEO & Director Philippe Martin - Chief R&D Officer Corinne Le Goff - Chie...

3 months ago - Seeking Alpha

Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Drugmaker Viatris beat third-quarter estimates for profit and revenue on Thursday, driven by strong demand for its branded drugs in China and emerging markets.

3 months ago - Reuters

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Delivers Total Revenues in Line With Expectations, Reflecting Strong Execution of its Global Business Makes Late-Stage Pipeline Progress Including NDA Submission for Low-Dose Estrogen Weekly Patch Acq...

3 months ago - PRNewsWire

Viatris Announces Quarterly Dividend

PITTSBURGH , Nov. 4, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on November 3, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued ...

3 months ago - PRNewsWire

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

Teva Pharmaceuticals and Viatris occupy leading positions in the generic drugs market, valued at more than $613 billion in 2030. Each of them has advantages and "dark spots" in their portfolios of FDA...

Other symbols: TEVA
4 months ago - Seeking Alpha

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Strengthens Viatris' Presence in Japan With the Addition of Two Innovative Assets Targeting Areas of Significant Unmet Medical Need Leverages Existing Infrastructure and Expertise in Central Nervous S...

4 months ago - PRNewsWire

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deli...

Other symbols: AESAMCRAREBMYCAGCPBDOC
4 months ago - Seeking Alpha

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

PITTSBURGH , Oct. 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2025. This is the f...

4 months ago - PRNewsWire

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

PITTSBURGH , Oct. 1, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at 8:30 a.m...

4 months ago - PRNewsWire

Viatris: Indore Plant Could Boost 2026 Numbers

Viatris continues to struggle with declining sales across all regions, with Q2-2025 net sales down 7% year over year. VTRS's Indore plant issues have significantly impacted results, but a full recover...

4 months ago - Seeking Alpha